Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience: JPN logoLink to Journal of Psychiatry & Neuroscience: JPN
. 2000 Jan;25(1):25–32.

Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial.

E Leinonen 1, U Lepola 1, H Koponen 1, J Turtonen 1, A Wade 1, H Lehto 1
PMCID: PMC1407706  PMID: 10721681

Abstract

OBJECTIVE: To examine the effects of long-term treatment with citalopram or clomipramine on subjective phobic symptoms in patients with panic disorder. DESIGN: Double-blind, parallel-group, five-arm study. PATIENTS: Patients aged 18 to 65 years with panic disorder (DMS-III-R diagnosis) and with no major depressive symptoms. INTERVENTIONS: Four hundred and seventy-five patients were randomized to 8 weeks of treatment with either citalopram (10 to 15 mg per day; 20 to 30 mg per day; or 40 to 60 mg per day), clomipramine (60 to 90 mg per day) or placebo. Two hundred and seventy-nine patients continued treatment after the 8-week acute phase. OUTCOME MEASURES: Phobic symptoms were assessed using the Phobia Scale and the Symptom Checklist's (SCL-90) phobia-related factors. RESULTS: At all dosages, citalopram was more efficacious than placebo, with 20 to 30 mg generally being the most effective dosage. Citalopram (20 to 30 mg) generally decreased phobic symptoms significantly more than placebo after Month 3. Interpersonal sensitivity decreased when measured on the respective SCL-90 sub-scale. Alleviation of phobic symptoms generally continued to increase towards the end of the treatment. The effect of clomipramine was not as consistent. CONCLUSIONS: All active treatment groups, especially the group receiving 20 to 30 mg per day of citalopram, effectively controlled phobic symptoms in patients with panic disorder. Long-term treatment with citalopram further decreased phobic symptoms.

Full text

PDF
24

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol. 1995 Mar;10(1):45–49. doi: 10.1097/00004850-199503000-00006. [DOI] [PubMed] [Google Scholar]
  2. Derogatis L. R., Lipman R. S., Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull. 1973 Jan;9(1):13–28. [PubMed] [Google Scholar]
  3. Hoehn-Saric R., McLeod D. R., Hipsley P. A. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol. 1993 Oct;13(5):321–326. [PubMed] [Google Scholar]
  4. Humble M., Wistedt B. Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of citalopram in panic disorders. Int Clin Psychopharmacol. 1992 Jun;6 (Suppl 5):21–39. [PubMed] [Google Scholar]
  5. Katschnig H., Amering M., Stolk J. M., Klerman G. L., Ballenger J. C., Briggs A., Buller R., Cassano G., Garvey M., Roth M. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 1995 Oct;167(4):487–494. doi: 10.1192/bjp.167.4.487. [DOI] [PubMed] [Google Scholar]
  6. Kessler R. C., Stang P. E., Wittchen H. U., Ustun T. B., Roy-Burne P. P., Walters E. E. Lifetime panic-depression comorbidity in the National Comorbidity Survey. Arch Gen Psychiatry. 1998 Sep;55(9):801–808. doi: 10.1001/archpsyc.55.9.801. [DOI] [PubMed] [Google Scholar]
  7. Koponen H., Lepola U., Leinonen E., Jokinen R., Penttinen J., Turtonen J. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand. 1997 Nov;96(5):343–346. doi: 10.1111/j.1600-0447.1997.tb09927.x. [DOI] [PubMed] [Google Scholar]
  8. Lepola U. M., Wade A. G., Leinonen E. V., Koponen H. J., Frazer J., Sjödin I., Penttinen J. T., Pedersen T., Lehto H. J. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry. 1998 Oct;59(10):528–534. doi: 10.4088/jcp.v59n1006. [DOI] [PubMed] [Google Scholar]
  9. Lepola U., Koponen H., Leinonen E. A naturalistic 6-year follow-up study of patients with panic disorder. Acta Psychiatr Scand. 1996 Mar;93(3):181–183. doi: 10.1111/j.1600-0447.1996.tb10628.x. [DOI] [PubMed] [Google Scholar]
  10. Marks I. M., Mathews A. M. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263–267. doi: 10.1016/0005-7967(79)90041-x. [DOI] [PubMed] [Google Scholar]
  11. Modigh K., Westberg P., Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992 Aug;12(4):251–261. [PubMed] [Google Scholar]
  12. Montgomery S. A., Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382–389. doi: 10.1192/bjp.134.4.382. [DOI] [PubMed] [Google Scholar]
  13. Noyes R., Jr, Garvey M. J., Cook B. L. Follow-up study of patients with panic disorder and agoraphobia with panic attacks treated with tricyclic antidepressants. J Affect Disord. 1989 Mar-Jun;16(2-3):249–257. doi: 10.1016/0165-0327(89)90080-3. [DOI] [PubMed] [Google Scholar]
  14. Oehrberg S., Christiansen P. E., Behnke K., Borup A. L., Severin B., Soegaard J., Calberg H., Judge R., Ohrstrom J. K., Manniche P. M. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry. 1995 Sep;167(3):374–379. doi: 10.1192/bjp.167.3.374. [DOI] [PubMed] [Google Scholar]
  15. Sheehan D. V., Harnett-Sheehan K. The role of SSRIs in panic disorder. J Clin Psychiatry. 1996;57 (Suppl 10):51–60. [PubMed] [Google Scholar]
  16. Sheehan D. V., Raj B. A., Trehan R. R., Knapp E. L. Serotonin in panic disorder and social phobia. Int Clin Psychopharmacol. 1993 Nov;8 (Suppl 2):63–77. doi: 10.1097/00004850-199311002-00010. [DOI] [PubMed] [Google Scholar]
  17. Wade A. G., Lepola U., Koponen H. J., Pedersen V., Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry. 1997 Jun;170:549–553. doi: 10.1192/bjp.170.6.549. [DOI] [PubMed] [Google Scholar]
  18. den Boer J. A., Westenberg H. G., De Leeuw A. S., van Vliet I. M. Biological dissection of anxiety disorders: the clinical role of selective serotonin reuptake inhibitors with particular reference to fluvoxamine. Int Clin Psychopharmacol. 1995 Jan;9 (Suppl 4):47–52. [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES